754 related articles for article (PubMed ID: 24658051)
1. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.
Chan CJ; Martinet L; Gilfillan S; Souza-Fonseca-Guimaraes F; Chow MT; Town L; Ritchie DS; Colonna M; Andrews DM; Smyth MJ
Nat Immunol; 2014 May; 15(5):431-8. PubMed ID: 24658051
[TBL] [Abstract][Full Text] [Related]
2. Interaction between nectin-1 and the human natural killer cell receptor CD96.
Holmes VM; Maluquer de Motes C; Richards PT; Roldan J; Bhargava AK; Orange JS; Krummenacher C
PLoS One; 2019; 14(2):e0212443. PubMed ID: 30759143
[TBL] [Abstract][Full Text] [Related]
3. Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.
Sun H; Huang Q; Huang M; Wen H; Lin R; Zheng M; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
Hepatology; 2019 Jul; 70(1):168-183. PubMed ID: 30411378
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer.
Peng YP; Xi CH; Zhu Y; Yin LD; Wei JS; Zhang JJ; Liu XC; Guo S; Fu Y; Miao Y
Oncotarget; 2016 Oct; 7(41):66586-66594. PubMed ID: 27626490
[TBL] [Abstract][Full Text] [Related]
6. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins.
de Andrade LF; Smyth MJ; Martinet L
Immunol Cell Biol; 2014 Mar; 92(3):237-44. PubMed ID: 24343663
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.
Blake SJ; Stannard K; Liu J; Allen S; Yong MC; Mittal D; Aguilera AR; Miles JJ; Lutzky VP; de Andrade LF; Martinet L; Colonna M; Takeda K; Kühnel F; Gurlevik E; Bernhardt G; Teng MW; Smyth MJ
Cancer Discov; 2016 Apr; 6(4):446-59. PubMed ID: 26787820
[TBL] [Abstract][Full Text] [Related]
8. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.
Stanietsky N; Rovis TL; Glasner A; Seidel E; Tsukerman P; Yamin R; Enk J; Jonjic S; Mandelboim O
Eur J Immunol; 2013 Aug; 43(8):2138-50. PubMed ID: 23677581
[TBL] [Abstract][Full Text] [Related]
9. Coming of Age: CD96 Emerges as Modulator of Immune Responses.
Georgiev H; Ravens I; Papadogianni G; Bernhardt G
Front Immunol; 2018; 9():1072. PubMed ID: 29868026
[TBL] [Abstract][Full Text] [Related]
10. Contribution of inhibitory receptor TIGIT to NK cell education.
He Y; Peng H; Sun R; Wei H; Ljunggren HG; Yokoyama WM; Tian Z
J Autoimmun; 2017 Jul; 81():1-12. PubMed ID: 28438433
[TBL] [Abstract][Full Text] [Related]
11. CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1.
Du X; de Almeida P; Manieri N; de Almeida Nagata D; Wu TD; Harden Bowles K; Arumugam V; Schartner J; Cubas R; Mittman S; Javinal V; Anderson KR; Warming S; Grogan JL; Chiang EY
Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11731-E11740. PubMed ID: 30504141
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
[TBL] [Abstract][Full Text] [Related]
13. CD155, an onco-immunologic molecule in human tumors.
Gao J; Zheng Q; Xin N; Wang W; Zhao C
Cancer Sci; 2017 Oct; 108(10):1934-1938. PubMed ID: 28730595
[TBL] [Abstract][Full Text] [Related]
14. Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade.
Cluxton CD; Spillane C; O'Toole SA; Sheils O; Gardiner CM; O'Leary JJ
PLoS One; 2019; 14(3):e0211538. PubMed ID: 30908480
[TBL] [Abstract][Full Text] [Related]
15. [CD226, TIGIT and CD96 regulate NK cell function and participate in anti-tumor immunity].
Zhang H; Liu R; Zhang Y; Liu X; Chen L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Sep; 39(9):852-856. PubMed ID: 37732582
[TBL] [Abstract][Full Text] [Related]
16. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.
Lupo KB; Matosevic S
J Hematol Oncol; 2020 Jun; 13(1):76. PubMed ID: 32532329
[TBL] [Abstract][Full Text] [Related]
17. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
18. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
19. CD96 as a Potential Immune Regulator in Cancers.
Feng S; Isayev O; Werner J; Bazhin AV
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674817
[TBL] [Abstract][Full Text] [Related]
20. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.
Bottino C; Castriconi R; Pende D; Rivera P; Nanni M; Carnemolla B; Cantoni C; Grassi J; Marcenaro S; Reymond N; Vitale M; Moretta L; Lopez M; Moretta A
J Exp Med; 2003 Aug; 198(4):557-67. PubMed ID: 12913096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
